Karyopharm Therapeutics

NCT01986348

Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas

NCT02088541

Selinexor (KPT-330) in Older Patients With Relapsed AML

NCT02025985

Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies

NCT02146833

SHIP (Selinexor in Hormone Insensitive Prostate Cancer)

NCT02228525

Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes

NCT02250885

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

NCT02213133

Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas

NCT02249091

A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

NCT02138786

Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation

NCT02227251

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02314247

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

NCT02336815

Selinexor Treatment of Refractory Myeloma

NCT02351505

Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer

NCT02402764

Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)

NCT02436707

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

NCT02431351

Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients

NCT02628704

Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma

NCT03071276

Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia

NCT03466827

Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma

NCT03193437

Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy

NCT03627403

Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

NCT04349098

Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection

NCT04355676

Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19

NCT04414475

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

NCT04661137

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

NCT04562870

A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis

NCT04768881

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

NCT04854434

A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

NCT04717700

Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients

NCT04782687

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

NCT04925193

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

NCT04843579

Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients

NCT05170789

Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma

NCT05530421

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

NCT05597345

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

NCT05983276

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

NCT05820763

Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

NCT05980806

A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia